Faris El Refaie – VP & General Manager, Pharma Canada

Faris was appointed to the role of VP and General Manager in August 2020 and is responsible for all pharmaceutical operations for GSK in Canada. He currently sits on the Canadian Country Management Board representing the Pharma business and is a prominent member of the Pharma Leadership Team. He joined GSK after spending the last 20+ years at AstraZeneca and recently returned to Canada from the UK.

Prior to joining GSK, Faris was the Global Commercial VP leading the Lynparza & DNA Damage Response (DDR) Franchise globally where he successfully launched Lynparza in five indications across four tumor types, as well as a rare disease product Koselugo for NF1-PN, while managing both through a complex global alliance with Merck.  Faris also led the Biosimilars development and commercialization program globally.

Previously, Faris was the VP Oncology in Canada, where he built AstraZeneca's first cross-functional Business Unit and successfully launched Lynparza, Tagrisso and Imfinzi.  Faris also brings valuable leadership and commercial experience from his 4+ years spent in the US where, as Women's Cancer Franchise Head, he led Sales, Marketing and Diagnostic teams across many promoted brands.

Faris studied at McMaster University in Hamilton, Ontario, Canada, where he obtained two degrees, an Honours Bachelor of Science in Biochemistry and a Master of Business Administration in Marketing and Operations.